SCHEMBL4186155

SCHEMBL4186155

O=c1c2nccnc2n(Cc2ccccc2)c(=O)n1Cc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.58
THRB P10828 1/20 0.56
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4A O75164 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPT P10636 3/20 0.51
RXFP1 Q9HBX9 1/20 0.47
UBE2N P61088 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RGS4 P49798 1/20 0.46
RGS8 P57771 1/20 0.46
USP2 O75604 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171474 0.94 TP53 (0.60) TP53THRBKDM4EALDH1A1L3MBTL1
SCHEMBL4167289 0.93 KDM4E (0.55) TP53THRBKDM4EALDH1A1L3MBTL1
SCHEMBL4174618 0.92 TP53 (0.51) TP53THRBKDM4EALDH1A1L3MBTL1
SCHEMBL4171721 0.89 TP53 (0.51) TP53THRBKDM4EALDH1A1L3MBTL1
SCHEMBL4173503 0.85 TP53 (0.51) TP53THRBTSHRMAPTUBE2N
SCHEMBL4171480 0.85 MAPT (0.56) TP53THRBKDM4EALDH1A1NPSR1
SCHEMBL4181523 0.83 UBE2N (0.49) TP53THRBKDM4EALDH1A1TSHR
SCHEMBL13888992 0.82 UBE2N (0.48) TP53THRBKDM4EALDH1A1TSHR
SCHEMBL4168727 0.82 UBE2N (0.48) TP53THRBKDM4EALDH1A1TSHR
SCHEMBL4188895 0.79 TP53 (0.46) TP53THRBHTTMAPTUBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088439-A1 Diazinane Compounds ASTRAZENECA AB (SE) 2009-04-02 US claimed
WO-2009041905-A1 PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS ASTRAZENECA AB (SE) 2009-04-02 WO claimed
US-20090088439-A1 Diazinane Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088439-A1 Diazinane Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088439-A1 Diazinane Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
WO-2009041905-A1 PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS ASTRAZENECA AB (SE) 2009-04-02 WO disclosed
WO-2009041905-A1 PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS ASTRAZENECA AB (SE) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088439-A1 Diazinane Compounds GABRB1, GRPR, GIPR TP53 4809/4885THRB 619/4885KDM4E 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.